Titanovo Logo
Back to Cell Types

U266B1Homo sapiens (Human)Cancer cell line

Also known as: U266-B1, U266 B1, U-266, U 266, U266, U266S, U266BL, U266 Bl, 266 Bl

🤖 AI SummaryBased on 13 publications

Quick Overview

Human multiple myeloma cell line with B-cell origin, used in cancer research.

Detailed Summary

U266B1 is a human multiple myeloma cell line derived from B-cells, widely used in cancer research. It is characterized by its ability to model the disease in vitro, providing insights into myeloma biology and drug responses. The cell line is known for its expression of specific markers and its utility in studying genetic and molecular mechanisms of myeloma progression. Research on U266B1 has contributed to understanding the role of various pathways, including those involving IL-6 and MYC, in myeloma development and treatment resistance.

Research Applications

Cancer researchDrug screeningMolecular mechanism studies

Key Characteristics

B-cell originMultiple myeloma modelIL-6 dependent
Generated on 6/15/2025

Basic Information

Database IDCVCL_0566
SpeciesHomo sapiens (Human)
Tissue SourcePeripheral blood[UBERON:UBERON_0000178]

Donor Information

Age53
Age CategoryAdult
SexMale

Disease Information

DiseasePlasma cell myeloma
LineageLymphoid
SubtypePlasma Cell Myeloma
OncoTree CodePCM

DepMap Information

Source TypeATCC
Source IDACH-000626_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleBRAFp.Lys601Asn (c.1803A>T)Heterozygous-from parent cell line U266B1
MutationSimpleMSH6p.Gly141Asp (c.422G>A)Heterozygous-from parent cell line U266B1
MutationSimpleTP53p.Ala161Thr (c.481G>A)Unspecified-PubMed=15735012
MutationSimpleTRAF3p.Lys550Leufs*3 (c.1648_1649insT)Homozygous-from parent cell line U266B1

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X,Y
CSF1PO
12,13
D10S1248
14
D12S391
18
D13S317
12
D16S539
10
D18S51
12,14
D19S433
13,15
D1S1656
12,15
D21S11
28,29
D22S1045
15,16
D2S1338
20,23
D2S441
10,11
D3S1358
17
D5S818
11,12
D6S1043
11,17
D7S820
11,12
D8S1179
13
DYS391
10
FGA
18
Penta D
10,13
Penta E
10,12
TH01
5,7
TPOX
8
vWA
17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Addiction to c-MYC in multiple myeloma.";

Holien T., Vatsveen T.K., Hella H., Waage A., Sundan A.

Blood 120:2450-2453(2012).

DOIPubMed

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOIPubMedPMC

Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis.

Sirota M., Wiita A.P.

Leukemia 34:2754-2765(2020).

DOIPubMedPMC

The LL-100 panel: 100 cell lines for blood cancer studies.";

MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.

Sci. Rep. 9:8218-8218(2019).

DOIPubMedPMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOIPubMedPMC

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOIPubMedPMC

Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways.

Pellat-Deceunynck C.

J. Hematol. Oncol. 11:137.1-137.13(2018).

DOIPubMedPMC

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

Yang H.H., Koeffler H.P.

BMC Cancer 18:940.1-940.13(2018).

DOIPubMedPMC

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

DOIPubMedPMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOIPubMedPMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOIPubMedPMC

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

DOIPubMed

A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines.

Moreau-Aubry A., Amiot M., Pellat-Deceunynck C.

Cytometry A 87:285-288(2015).

DOIPubMed

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

DOIPubMed

Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels.

Greenberg A.J., Walters D.K., Kumar S.K., Rajkumar S.V., Jelinek D.F.

Eur. J. Haematol. 91:504-513(2013).

DOIPubMedPMC

Karyotypic variability of human myeloma cell lines.";

Turilova V.I., Smirnova T.D.

Tsitologiia 54:621-636(2012).

DOIPubMed

Multiple myeloma cell lines.";

Jernberg-Wiklund H., Nilsson K.

(In book chapter) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York; USA (2000).

DOI

The leukemia-lymphoma cell line factsbook.";

Drexler H.G.

(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).

DOI

Mutations of the p53 gene in human myeloma cell lines.";

Theillet C., Klein B.

Oncogene 7:1015-1018(1992).

PubMed

Reciprocal regulatory effects of IL-4 on cell growth and immunoglobulin production in Ig-secreting human B-cell lines.

Renz H., Or R., Domenico J., Leung D.Y.M., Gelfand E.W.

Clin. Immunol. Immunopathol. 64:233-241(1992).

DOIPubMed

Estimation of interleukin 6 production by reverse transcriptase-polymerase chain reaction in four human myeloma cell lines.

Koishihara Y., Ohsugi Y., Ohno Y., Imura H.

Leuk. Res. 15:1043-1050(1991).

DOIPubMed

Expression of leukocyte common antigen (CD45) on various human leukemia/lymphoma cell lines.

Nakano A., Harada T., Morikawa S., Kato Y.

Acta Pathol. Jpn. 40:107-115(1990).

DOIPubMed

Phenotypic analysis of human myeloma cell lines.";

Bataille F.-R.

Blood 73:566-572(1989).

DOIPubMed

Isoenzyme studies in human leukemia-lymphoma cell lines -- 1. carboxylic esterase.

Drexler H.G., Gaedicke G., Minowada J.

Leuk. Res. 9:209-229(1985).

DOIPubMed

Isoenzyme studies in human leukemia-lymphoma cell lines -- III. Beta-hexosaminidase (E.C. 3.2.1.30).

Drexler H.G., Gaedicke G., Minowada J.

Leuk. Res. 9:549-559(1985).

DOIPubMed

Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid phosphatase.

Drexler H.G., Gaedicke G., Minowada J.

Leuk. Res. 9:537-548(1985).

DOIPubMed

Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient.

Nilsson K., Bennich H., Johansson S.G.O., Ponten J.

Clin. Exp. Immunol. 7:477-489(1970).

PubMedPMC

Characteristics of established myeloma and lymphoblastoid cell lines derived from an E myeloma patient: a comparative study.

Nilsson K.

Int. J. Cancer 7:380-396(1971).

DOIPubMed

Determination of the optimal human cell lines for development of human hybridomas.

Foon K.A.

J. Immunol. 131:1201-1204(1983).

DOIPubMed

Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma.

Kuehl W.M.

Proc. Natl. Acad. Sci. U.S.A. 93:13931-13936(1996).

DOIPubMedPMC

Telomere analysis by fluorescence in situ hybridization and flow cytometry.

Roos G.

Nucleic Acids Res. 26:3651-3656(1998).

DOIPubMedPMC

Fluorescence in situ hybridization analysis shows the frequent occurrence of 14q32.3 rearrangements with involvement of immunoglobulin switch regions in myeloma cell lines.

Lokhorst H.M., Clevers H.C., Bast B.J.E.G.

Cancer Genet. Cytogenet. 109:99-107(1999).

DOIPubMed

Detection of MUM1/IRF4-IgH fusion in multiple myeloma.";

Shimizu S., Taniwaki M., Ueda R.

Leukemia 13:1812-1816(1999).

DOIPubMed

Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells.";

Bataille F.-R., Amiot M.

Br. J. Haematol. 107:392-395(1999).

DOIPubMed

Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia.

Drexler H.G., Matsuo Y.

Leuk. Res. 24:681-703(2000).

DOIPubMed

Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells.

Sundan A.

Blood 97:516-522(2001).

DOIPubMed

Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.

Kuehl W.M., Bergsagel P.L.

Blood 97:729-736(2001).

DOIPubMed

Ectopic expression of MAFB gene in human myeloma cells carrying (14;20)(q32;q11) chromosomal translocations.

Sonta S.-i., Nitta M., Taniwaki M., Ueda R.

Jpn. J. Cancer Res. 92:638-644(2001).

DOIPubMedPMC

Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma.

Hideshima T., Goyal R.K., Hurley L.H., Anderson K.C., Munshi N.C.

Mol. Cancer Ther. 2:825-833(2003).

PubMed

Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma.

Taniwaki M., Inazawa J.

Am. J. Pathol. 165:71-81(2004).

DOIPubMedPMC

The phenotype of normal, reactive and malignant plasma cells. Identification of 'many and multiple myelomas' and of new targets for myeloma therapy.

Moreau P., Amiot M., Pellat-Deceunynck C.

Haematologica 91:1234-1240(2006).

PubMed

Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease.

Lambertenghi-Deliliers G., Bertoni F., Neri A.

Genes Chromosomes Cancer 46:226-238(2007).

DOIPubMed

Induction of class II major histocompatibility complex expression in human multiple myeloma cells by retinoid.

Sanda T., Iida S., Kayukawa S., Ueda R.

Haematologica 92:115-120(2007).

DOIPubMed

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

Stewart A.K., Carpten J.D., Bergsagel P.L.

Cancer Cell 12:131-144(2007).

DOIPubMedPMC

Characterization of MYC translocations in multiple myeloma cell lines.

Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.

J. Natl. Cancer Inst. Monogr. 39:25-31(2008).

DOIPubMedPMC

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOIPubMedPMC

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

DOIPubMedPMC

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.

Pellat-Deceunynck C.

Haematologica 96:574-582(2011).

DOIPubMedPMC

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOIPubMedPMC

Web Resources

keatslab.orgtcpaportal.org